Aytu BioPharma, Inc. (AYTU)
USD 1.03
(0.98%)
USD 1.03
(0.98%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 | 10.87 Million USD | -26.07% |
| 2023 | 14.71 Million USD | 3.04% |
| 2022 | 14.27 Million USD | 409.24% |
| 2021 | 2.8 Million USD | 286.56% |
| 2020 | 725.37 Thousand USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 100.0% |
| 2015 | -425.89 Thousand USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q4 | 10.87 Million USD | 0.0% |
| 2024 Q3 | 5 Million USD | -100.0% |
| 2024 Q2 | 14.97 Million USD | 0.92% |
| 2024 Q1 | 14.84 Million USD | 0.88% |
| 2023 Q3 | 11.38 Million USD | -21.65% |
| 2023 Q2 | 14.53 Million USD | 7.18% |
| 2023 Q4 | 14.71 Million USD | 29.22% |
| 2023 Q1 | 13.56 Million USD | -5.04% |
| 2023 FY | 14.71 Million USD | 3.04% |
| 2022 Q1 | 2.91 Million USD | 3.85% |
| 2022 FY | 14.27 Million USD | 409.24% |
| 2022 Q4 | 14.27 Million USD | -13.84% |
| 2022 Q3 | 16.57 Million USD | 482.53% |
| 2022 Q2 | 2.84 Million USD | -2.3% |
| 2021 Q4 | 2.8 Million USD | -85.84% |
| 2021 FY | 2.8 Million USD | 286.56% |
| 2021 Q1 | 237.49 Thousand USD | -67.26% |
| 2021 Q2 | 211.05 Thousand USD | -11.13% |
| 2021 Q3 | 19.8 Million USD | 9282.59% |
| 2020 Q2 | 291.81 Thousand USD | -7.2% |
| 2020 Q3 | 804.39 Thousand USD | 175.65% |
| 2020 FY | 725.37 Thousand USD | 0.0% |
| 2020 Q4 | 725.37 Thousand USD | -9.82% |
| 2020 Q1 | 314.45 Thousand USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2019 Q3 | 5.13 Million USD | 1.96% |
| 2019 Q4 | - USD | -100.0% |
| 2019 Q2 | 5.03 Million USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2016 Q2 | 4.92 Million USD | 1.99% |
| 2016 Q4 | - USD | -100.0% |
| 2016 FY | - USD | 100.0% |
| 2016 Q1 | 4.82 Million USD | 1232.99% |
| 2016 Q3 | 9797.00 USD | -99.8% |
| 2015 Q4 | -425.89 Thousand USD | 0.0% |
| 2015 FY | -425.89 Thousand USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Bright Green Corporation | 201.78 Thousand USD | -5290.444% |
| Alpha Teknova, Inc. | 13.25 Million USD | 17.916% |
| ANI Pharmaceuticals, Inc. | 309.66 Million USD | 96.488% |
| Aquestive Therapeutics, Inc. | 91.07 Million USD | 88.057% |
| Collegium Pharmaceutical, Inc. | 489.96 Million USD | 97.78% |
| Cosmos Health Inc. | 3.03 Million USD | -258.345% |
| Journey Medical Corporation | 14.62 Million USD | 25.612% |
| Embecta Corp. | 1.62 Billion USD | 99.331% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 97.831% |
| Dynavax Technologies Corporation | 252.41 Million USD | 95.691% |
| Intra-Cellular Therapies, Inc. | 13.32 Million USD | 18.378% |
| Pacira BioSciences, Inc. | 513.79 Million USD | 97.883% |
| PainReform Ltd. | 30 Thousand USD | -36156.667% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -1917.865% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -1917.865% |
| SCYNEXIS, Inc. | 12.15 Million USD | 10.544% |
| Safety Shot Inc | 304.9 Thousand USD | -3467.317% |
| China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | -9186.342% |
| Procaps Group, S.A. | 28.41 Million USD | 61.714% |
| Theratechnologies Inc. | 51.26 Million USD | 78.781% |
| Harrow Health, Inc. | 183.17 Million USD | 94.062% |
| Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -12402.299% |
| Biofrontera Inc. | 804 Thousand USD | -1252.861% |
| DURECT Corporation | 2.7 Million USD | -302.554% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | 67.234% |
| Cronos Group Inc. | 1.55 Million USD | -597.691% |
| OptiNose, Inc. | 611 Thousand USD | -1680.196% |
| Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | 97.817% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | 68.187% |
| RedHill Biopharma Ltd. | 455 Thousand USD | -2290.549% |
| Organogenesis Holdings Inc. | 60.74 Million USD | 82.094% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Cumberland Pharmaceuticals Inc. | 12.78 Million USD | 14.918% |
| Radius Health, Inc. | 339.66 Million USD | 96.798% |
| Universe Pharmaceuticals INC | - USD | -Infinity% |
| ProPhase Labs, Inc. | 10.25 Million USD | -6.034% |
| Phibro Animal Health Corporation | 458.28 Million USD | 97.627% |
| Procaps Group S.A. | 28.41 Million USD | 61.714% |
| Alvotech | 1.02 Billion USD | 98.942% |
| TherapeuticsMD, Inc. | 6.53 Million USD | -66.519% |
| Viatris Inc. | 16.18 Billion USD | 99.933% |
| Rockwell Medical, Inc. | 8.29 Million USD | -31.159% |
| SIGA Technologies, Inc. | 335.99 Thousand USD | -3137.289% |
| Tilray Brands, Inc. | 287.93 Million USD | 96.222% |
| Lifecore Biomedical, Inc. | 120.51 Million USD | 90.974% |
| Shineco, Inc. | 10.01 Million USD | -8.582% |
| PetIQ, Inc. | 437.82 Million USD | 97.516% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 210 Thousand USD | -5079.524% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 95.789% |
| Alimera Sciences, Inc. | 64.48 Million USD | 83.134% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 38.51 Million USD | 71.758% |
| Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | -7951.729% |
| Petros Pharmaceuticals, Inc. | 6.85 Million USD | -58.618% |
| Clever Leaves Holdings Inc. | 720 Thousand USD | -1410.694% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -48276.623% |
| Avadel Pharmaceuticals plc | 32.75 Million USD | 66.798% |
| Hempacco Co., Inc. | 5.93 Million USD | -83.392% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.02 Billion USD | 98.942% |
| Eagle Pharmaceuticals, Inc. | 56.21 Million USD | 80.651% |
| Lantheus Holdings, Inc. | 616.12 Million USD | 98.235% |
| Currenc Group, Inc. | 2.5 Million USD | -333.87% |
| Kamada Ltd. | 7.43 Million USD | -46.236% |
| Indivior PLC | 235.66 Million USD | 95.385% |
| Evoke Pharma, Inc. | 5 Million USD | -117.54% |
| Flora Growth Corp. | 942 Thousand USD | -1054.671% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -48276.623% |
| Evolus, Inc. | 120.35 Million USD | 90.963% |
| HUTCHMED (China) Limited | 48.18 Million USD | 77.428% |
| Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 98.154% |
| Akanda Corp. | 2.49 Million USD | -335.576% |